Boston Scientific Corp (XTER:BSX)
€ 86.5 -0.5 (-0.57%) Market Cap: 126.52 Bil Enterprise Value: 134.81 Bil PE Ratio: 74.93 PB Ratio: 6.45 GF Score: 79/100

Boston Scientific Corp Investor Update at TCT 2019 Transcript

Sep 27, 2019 / 07:00PM GMT
Susan Vissers Lisa;Jeffrey B. Mirviss
Boston Scientific Corporation - VP of IR;Boston Scientific

Hi, guys. It's noon, so we're going to get started. As people are getting settled, thank you very, very much for joining us here at the Boston Scientific Transvascular Cardio Therapeutics Conference 2019.

Really grateful for the opportunity here. And my name is Susie Lisa, I'm with the Investor Relations team at Boston Scientific, joined by my colleague Lauren Tengler. We have a great lineup of speakers for you today. We'll try and keep it tight to about 15 to 20 minutes of prepared remarks and then leave lots of time for your questions.

So to move right into, we will be making forward-looking statements today, and the usual regulatory disclaimers apply as well as from financial disclaimers, we encourage you to seek our latest 10-K and 10-Q filings with the SEC for a full discussion of risk factors.

And with that, I'm very happy to turn it over to Jeff Mirviss, our Senior Vice President and President of Peripheral Interventions. Thanks, Jeff.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot